Skip to main content

Table 2 Univariate and Cox regression model for AKI

From: An area under the concentration–time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria

Variable

No AKI

(n = 279)

AKI

(n = 114)

Pa

HR (95% CI)

Pb

Age, years

54.0 (47.0–64.0)

58.0 (50.8–66.0)

0.012

1.02 (1.01–1.03)

0.003

GFR, mL/min·1.73 m2

103.1 (74.0–121.3)

95.5 (66.2–110.6)

0.025

Furosemide

101 (36.2%)

53 (46.5%)

0.058

Use of nephrotoxic drugs

196 (70.3%)

93 (81.6%)

0.021

Polymyxin B dose and exposure

Dose/weight, mg/kg/day

2.0 (1.67–2.37)

2.31 (1.94–2.61)

 < 0.001

  

Daily dose ≥ 150 mg/day

178 (63.8%)

89 (78.1%)

0.006

  

cAUCss,24 h < 50 mg h/L

140 (50.2%)

15 (13.2%)

 < 0.001

 < 0.001

AUCss,24 h = 50–100 mg h/L

131 (47.0%)

64 (56.1%)

3.89 (2.17–6.97)

 < 0.001

AUCss,24 h > 100 mg h/L

8 (2.9%)

35 (30.7%)

16.29 (8.16–30.25)

 < 0.001

dC0h < 1.2 mg/L

173 (62.0%)

17 (14.9%)

 < 0.001

  

C0h = 1.2–2.8 mg/L

98 (35.1%)

66 (57.9%)

  

C0h > 2.8 mg/L

8 (2.9%)

31 (27.6%)

  
  1. AKI acute kidney injury; HR hazard ratio; CI confidence interval; GFR glomerular filtration rate; and AUCss,24 h the area under the curve across 24 h at steady state
  2. aderived from univariate analysis
  3. bderived from Cox regression analysis
  4. cAUCss,24 h < 50 mg h/L was taken as reference
  5. dC0h was not included in the Cox regression model due to collinearity with AUCss,24 h